Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320357 | 0.78 | NFKB1 (0.37) | NPSR1LMNASMN1; SMN2MEN1GAA | |
| SCHEMBL6325149 | 0.76 | NPSR1 (0.32) | NPSR1MAPTHTTPOLB | |
| SCHEMBL6320648 | 0.75 | NPSR1 (0.36) | NPSR1LMNASMN1; SMN2MEN1GAA | |
| SCHEMBL6325153 | 0.75 | NPSR1 (0.32) | NPSR1LMNASMN1; SMN2MEN1GAA | |
| SCHEMBL6318197 | 0.73 | KDM4E (0.32) | NPSR1LMNAGAAMAPT | |
| SCHEMBL6325102 | 0.71 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL6318202 | 0.69 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL6320719 | 0.68 | NPSR1 (0.32) | NPSR1LMNA | |
| SCHEMBL6395956 | 0.68 | KDM4E (0.32) | NPSR1LMNAGAAMAPT | |
| SCHEMBL6324431 | 0.67 | NFKB1 (0.35) | NPSR1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | claimed |
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | QUATRX PHARMACEUTICALS CO. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143349-A1 | Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels | APOB, LDLR, LPL | NPSR1 248/4885LMNA 144/4885SMN1; SMN2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.